<- Go Home
Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Market Cap
$114.2B
Volume
7.0M
Cash and Equivalents
$5.0B
EBITDA
$13.9B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$22.0B
Profit Margin
77.80%
52 Week High
$98.90
52 Week Low
$62.07
Dividend
3.36%
Price / Book Value
6.18
Price / Earnings
943.78
Price / Tangible Book Value
-11.00
Enterprise Value
$130.7B
Enterprise Value / EBITDA
9.26
Operating Income
$11.2B
Return on Equity
0.56%
Return on Assets
11.96
Cash and Short Term Investments
$6.7B
Debt
$23.2B
Equity
$18.4B
Revenue
$28.3B
Unlevered FCF
$9.7B
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium